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contribute to vascular tone and endothelial function, basal activity of this signaling cascade in cardiac myocytes is very low. PKG knock-down or loss-of function studies have found minimal impact on either cardiac morphology or function under rest conditions 2, 3 , and some even questioned its role in the heart 4 . However, as with an automotive brake, the influence of cGMP and PKG in hearts under stress is greater. Over the past decade, studies have shown that cGMP/PKG activation counters a broad array of acute and chronic cardiac stress responses, including those from beta-adrenergic stimulation 5 , ischemic injury 6 , pressure and volume overload 7, 8 , and doxorubicin cardiotoxicity 9 .
Methods to activate cGMP/PKG signaling have already been developed as clinical therapies, including those that enhance cGMP synthesis such as organic nitrates (e.g. isosorbide dinitrate), activate GC (e.g. cinaciguat or natriuretic peptides), and curtail cGMP-hydrolysis (e.g. sildenafil, tadalafil). All are either used or being studied in heart failure patients. PDE5 inhibitors were first thought to have negligible effects on the heart; however, research over the past decade has revealed substantial benefits in a variety of experimental and human cardiac diseases. Single-center trials testing sildenafil in dilated heart failure patients reported improvements in symptoms and exercise capacity, microvascular function, pulmonary hypertension, and cardiac morphology and function 10, 11 . The RELAX trial of 225 patients, an NIH-sponsored multicenter study testing the utility of sildenafil in patients with heart failure and a preserved ejection fraction (HFpEF), completed enrollment in early 2012, and results are anticipated later this year. Another muliticenter NIH trial of >2000 patients (PITCH-HF) will start shortly and test the efficacy of tadalafil in patients with heart failure and a reduced ejection fraction (HFrEF) who also have rest and/or exercise induced pulmonary hypertension. On the stimulation side, the combination of isosorbide dinitrite+hydralazine is approved for treating herapies, including those that enhance cGMP synthesis such as organic nitrates ( ( (e.g. g g i i iso so soso so sorb rb rbid ide dinitrate), activate GC (e.g. cinaciguat or natriuretic peptides), and curtail cGMP-hydrolysis (e.g. i ild ld den en enaf af afil il il, , ta ta tada d d la afi fi fil l) l). All are either used or being g g st stu udied in heart t f f failu ure re re p patients. PDE5 n nhi i ib bitors wer re e fi fi f rs s st th th thou u ugh gh ght t to to to h hav av ve e e n ne eg gl ligib b ble e e eff ff fe ec cts o on n n th th he he hea a art t t; h how ow we ev ever er r, , re rese se ear ar a ch ch ch o ov ve ver r th th t e e e The efficacy of treatments engaging the cGMP/PKG pathway depends upon specifics of the signaling, and this itself can be modified by heart disease. For example, an NO-mimetic leverages sGC to generate cGMP. However, in vascular and cardiac disease, sGC is often subject to oxidative stress that reduces its responsiveness to NO 12, 13 . Direct sGC agonists that are heme-(oxidative state) independent may circumvent this limitation 13 . Generating more cGMP becomes less effective if cGMP-PDEs are upregulated, and in this setting, inhibiting the appropriate PDEs becomes very useful. Neither elevated cGMP synthesis or hydrolysis is a feature of the normal heart, but it is in human HFrEF 14, 15 and experimental pressure-overload, supporting current efforts with PDE5 inhibition. Lastly, PKG itself needs to have something useful to do -that is a targetable pathway must exist whose modification by the kinase can offset cardiac maladaptation. Some diseases activate these pathways more than others. To date, PKG measurements include passive tension in isolated cardiac myocytes, and assays to assess various levels, activity, and post-translational modifications of proteins involved with the NO/NP-cGMP-PKG cascade. As these investigators have previously reported 18 , maximal passive myocyte stiffness was higher in HFpEF than HFrEF (or AS). Their earlier study showed this disparity could be eliminated by incubation with PKA, and in the current research, they found a similar result using PKG. This suggested a deficit of PKG activity in HFpEF that was more directly supported by several kinase assays. As to why PKG activity might be lower in HFpEF, the investigators found cGMP was also much reduced. Though correlated with lower pro-BNP expression, the latter was also observed in AS patients who had higher PKG activity. PDE5
protein expression appeared similar among groups. Rather, the authors highlighted greater oxidative/nitrosative stress in HFpEF, suggesting reduced NO-stimulated cGMP synthesis as the culprit.
The authors also performed sub-group analysis, examining myocyte passive stiffness, PKG activity, and cGMP levels in each group with or without diabetes mellitus (DM). HFpEF patients had the highest stiffness regardless of DM status. However, unlike DM-patients, both
HFpEF and AS with DM+ had similarly reduced PKG activity, raising questions about its role. Furthermore, despite low PKG activity in AS-DM+, these subjects had higher cGMP levels unlike HFpEF-DM+ patients. The investigators have previously shown that DM exacerbates myocyte passive stiffness in AS patients 19 , and this seems true in the current analysis though it was not mentioned. PKG activity also appeared to be about half in DM-AS versus AS alone, though significance not noted. The finding of similar improvement in myocyte stiffness in HFpEF (and HFrEF) to PKA (prior data 18 ) and now to PKG suggests the residue targets may be similar. Titin for example serves as a molecular spring, and both PKG and PKA modify the same residues in the variable N2b region that reduce its stiffness constant. The prior work raised questions about the use of beta-blockade in HFpEF, given its suppression of PKA. Rather than further stimulate PKA, however, the current study suggests a similar benefit can be obtained by cGMP/PKG stimulation.
The authors speculated that oxidation of titin may also play a role in HFpEF, though the rescue of stiffening by PKG alone in vitro argues for phosphorylation as a dominant mechanism.
The data also raise intriguing questions as to how one might increase PKG activity to treat HFpEF. Though PDE5 immunohistochemistry staining was similar among the groups, others have reported substantial upregulation of PDE5 expression in HFrEF compared to low levels in normal controls 14, 15 . Thus the current data could be consistent with upregulation in all groups. PDE5 activity was not assessed, and expression does not always reflect enzyme activity due to post-translational changes and alterations in protein localization and function (e.g.
hydrolysis of cGMP generated by sGC versus rGC) 20 . Lastly, the LV biopsy analysis reflects prior data 18 ) and now to PKG suggests the residue targets may be similar. Titin n f for or r e exa xa xamp mp mple le le erves as a molecular spring, and both PKG and PKA modify the same residues in the variable interesting to see nitrotyrosine data for these two sub-groups. Other studies have found ROS activation and ROS/NO imbalance in HFrEF models, indeed this has been suggested as pertinent to such patients who respond to isosorbide dinitrate+hydralazine. If HFpEF reflects greater NO-ROS imbalance, then perhaps direct heme-independent sGC activators such as cinaciguat would be a better choice given likely redox changes in sGC that blunt its NO response.
As more and more therapeutic avenues become available to modulate cGMP/PKG signaling, interest in this pathway and ways to leverage it for treating heart disease will continue to rise. The recent promising results from PDE5 inhibitor trials in HFrEF, and evidence of potency in HFpEF as well are moving this field forward, with pivotal clinical trials now underway. To date, natriuretic peptide therapy has been used sub-acutely -given the need for intravenous administration. Whether BNP or newer more stable and potent NPs are beneficial ack of specificity for peroxinitrite formation. While the authors suggest that a h hi ig ighe he h r r pr pr prev ev eval al alen ence of DM may have contributed to redox imbalance in HFpEF, their sub-set analysis found similar de epr pr pres es ssi si sion on n o o f f f cG G GM MP MP and PKG activity in HFpEF F F w w with or without t DM DM. . I I It t would have been when used chronically remains to be tested. Lastly, novel methods to improve NOS activity and/or sGC generation of cGMP are moving forward. Understanding how to best use these approaches will require appreciation of the balance between cGMP synthesis, hydrolysis, and PKG targeting. The Paulus laboratory and colleagues are to be congratulated for providing us valuable new insights in this regard.
